ADPKD Clinical Trial - Statin Therapy in Patients With Early Stage ADPKD

Status Active, not recruiting

Clinical Trial Summary

This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and benefits of pravastatin therapy in adults with ADPKD by evaluating 1) kidney volume as measured by kidney magnetic resonance imaging (MRI); 2) renal blood flow as measured by kidney magnetic resonance angiography (MRA); 3) kidney function as assessed by Glofil-125; 4) plasma and urine protein markers that will allow a better understanding of how pravastatin works in ADPKD; and 5) blood vessel stiffness as measured by carotid-femoral pulse wave velocity. These parameters will be measured at baseline and after 2 years of pravastatin or placebo treatment in 150 patients with ADPKD. ;

Study Design

Related Conditions & MeSH terms

ADPKD
Autosomal Dominant Polycystic Kidney
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant

Clinical Trial Details

NCT number	NCT03273413
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	August 31, 2017
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04310319` - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt	N/A
Completed	`NCT02776241` - Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease	N/A
Terminated	`NCT04152837` - Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease	Phase 3
Completed	`NCT03717883` - ADPKD Alterations in Hepatic Transporter Function
Recruiting	`NCT05014178` - Kidney Sodium Functional Imaging
Recruiting	`NCT05521191` - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease	Phase 1
Terminated	`NCT04064346` - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease	Phase 3
Completed	`NCT03203642` - Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD	Phase 2
Recruiting	`NCT04338048` - Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
Not yet recruiting	`NCT06100133` - Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?	Phase 2
Completed	`NCT01632605` - The Vienna RAP Pilot Study	N/A
Terminated	`NCT03918447` - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON	Phase 3
Recruiting	`NCT06416761` - Genetics in the Progression of Nephropathies
Not yet recruiting	`NCT05373264` - HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life	Phase 3
Recruiting	`NCT06085807` - Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
Completed	`NCT01853553` - Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Phase 3
Completed	`NCT04472624` - Short Term Induction of Ketosis in PKD	N/A
Not yet recruiting	`NCT03764605` - Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease	Phase 3
Completed	`NCT04680780` - Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	N/A
Completed	`NCT02161068` - Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping